Absorption Systems was issued a third U.S. patent for its CellPort Technologies portfolio of in vitro test systems. The new patent covers its MRP2 knockdown cell line and extends the patent coverage on the transporter knockdown technology beyond previously issued patents in the U.S., Europe, and Panama. The cell-based test systems are designed to allow drug developers to definitively predict the risk of clinical drug-drug interactions (DDIs) involving drug transporters.
 
The newly patented in vitro test systems were developed by Absorption Systems’ chief scientist, Dr. Ismael Hidalgo, who leads the company’s preclinical R&D, including collaborations with academic, industrial, and FDA scientists. Dr. Hidalgo said, “This patent further validates our commitment to develop better tools that predict clinical outcomes, improve drug safety, and save lives. CellPort Technologies can provide very definitive data on drug transporters, which is now required by regulatory agencies such as the FDA. And the technology is exclusive to Absorption Systems.”